天辰生物-B(01779)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01779 天辰生物-B

交易中 06-18 13:21:43

140.200

+0.200

+0.14%

最高142.000	最低137.000	成交量14.30万
今开140.000	昨收140.000	日振幅3.57%
总市值104.02亿	流通市值102.25亿	总股本7,419万
成交额1,990万	换手率0.20%	流通股本7,293万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01779","market":"HK","secType":"STK","nameCN":"天辰生物-B","latestPrice":140.2,"timestamp":1781760086753,"preClose":140,"halted":0,"volume":143000,"delay":0,"changeRate":0.0014285714285713475,"floatShares":72930300,"shares":74193200,"eps":-2.733,"marketStatus":"交易中","change":0.2,"latestTime":"06-18 13:21:43","open":140,"high":142,"low":137,"amount":19895775,"amplitude":0.035714,"askPrice":140.2,"askSize":200,"bidPrice":140.1,"bidSize":50,"shortable":0,"etf":0,"ttmEps":-2.62,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1781770200000},"marketStatusCode":2,"adr":0,"listingDate":1780588800000,"exchange":"SEHK","adjPreClose":140,"openAndCloseTimeList":[[1781746200000,1781755200000],[1781758800000,1781769600000]],"volumeRatio":1.548156,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01779","defaultTab":"news","newsList":[{"id":"2642237531","title":"天辰生物-B(01779)：LP-003针对季节性过敏性鼻炎适应症的III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2642237531","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642237531?lang=zh_cn&edition=full","pubTime":"2026-06-12 06:16","pubTimestamp":1781216203,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 发布公告，LP-003针对季节性过敏性鼻炎的III期临床试验已达到预先设定的主要终点，且该等结果在统计学及临床方面均具有高度重要性。LP-003针对季节性过敏性鼻炎适应症的III期临床试验是一项在中国开展的多中心、随机、双盲、安慰剂对照的III期临床研究，旨在比较LP-003与安慰剂治疗经标准治疗控制不佳的中重度季节性过敏性鼻炎的效果。主要排除标准为患有季节性过敏性鼻炎以外的合并症的患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","01779","III"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1123467918","title":"天辰生物-B：LP-3治疗季节性过敏性鼻炎III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1123467918","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123467918?lang=zh_cn&edition=full","pubTime":"2026-06-12 06:13","pubTimestamp":1781215995,"startTime":"0","endTime":"0","summary":"天辰生物-B宣布，其用于治疗季节性过敏性鼻炎的候选药物LP-3，在关键的III期临床试验中成功达到了预设的主要疗效终点。这一积极结果标志着该药物在临床开发道路上取得了重大进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642462623","title":"进入最后一个月倒计时，天辰生物-B(01779)能否在入通前撑起高位估值？","url":"https://stock-news.laohu8.com/highlight/detail?id=2642462623","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642462623?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:26","pubTimestamp":1781004367,"startTime":"0","endTime":"0","summary":"上市次日，天辰生物场内表现较为低迷，股价全天在水下波动，最终收跌6.83%。此次天辰生物的发行比例是19.13%，基石锁定49.96%，流通盘约为6.82亿港元，其释出的公开发售数量为28387手，并且入场费达到4851.44港元。目前天辰生物检讨周期内日平均市值为90.77亿港元，市值覆盖率为94.61%，而截至6月8日公司收盘价为124港元。但就在这种情况下，天辰生物的此次IPO发行市值却达到了71.27亿港元，较C轮估值大涨226.57%，而这在短期内或透支了公司估值成长预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118653094","title":"异动解读｜天辰生物-B盘中上涨6.37%，上市次日延续IPO超购热度","url":"https://stock-news.laohu8.com/highlight/detail?id=1118653094","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118653094?lang=zh_cn&edition=full","pubTime":"2026-06-09 09:33","pubTimestamp":1780968791,"startTime":"0","endTime":"0","summary":"6月9日，天辰生物-B盘中上涨6.37%，报139.3港元，成交额775.71万港元，较招股价96.06港元累计溢价约45%。消息面上，天辰生物-B于6月5日正式登陆港交所，其香港公开发售部分获得高达4762.58倍超额认购，一手中签率仅约2%，市场认购热情极高。天辰生物是一家临床阶段生物制药公司，专注于过敏性及自身免疫性疾病生物药物的自主发现与开发，核心产品LP-003为抗IgE抗体，已在中国启动八项临床试验。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641168031","title":"港股收盘(06.05) | 恒指收跌1.15%失守两万五 半导体股显著回调 三新股首日表现分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2641168031","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641168031?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:32","pubTimestamp":1780648331,"startTime":"0","endTime":"0","summary":"截至收盘，恒生指数跌1.15%或291.45点，报24961.95点，全日成交额3428.05亿港元；恒生国企指数跌0.77%，报8436.63点；恒生科技指数跌1.75%，报4888.39点。截至收盘，涨6%，报143.2港元，成交额3亿港元，贡献恒指1.67点。截至收盘，澜起科技跌9.21%，报368.8港元；兆易创新跌8.02%，报723.0港元；中芯国际跌7.18%，报75.65港元；华虹半导体跌7.16%，报145.3港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450691.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09115","SOXY","03143","MCHmain","HSI","03419","07200","BK1526","HSImain","LU0149534421.HKD","PSI","TEKX","03037","SSG","CHPS","SMHX","HHImain","VGT","02290","MHImain","USD","SOXQ","XSD","513600","01779","SG9999000327.SGD","FTXL","SOXS","00981","LU0067412154.USD","SOXL","SMH","02800","82800","CHPY","06809","02833","159582","LU0211977185.USD","VXUS","00316","SOXX","LU1152091754.HKD","83115","02888","07500","03115","07300","STAN.UK","BK1163"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193234584","title":"异动解读 | 天辰生物-B首日挂牌盘中大涨54.80%，获超4700倍超额认购引爆市场热情","url":"https://stock-news.laohu8.com/highlight/detail?id=1193234584","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193234584?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:35","pubTimestamp":1780623326,"startTime":"0","endTime":"0","summary":"天辰生物-B今日盘中大幅上涨54.80%，成为市场关注的焦点。消息面上，天辰生物-B今日正式在港交所主板挂牌上市，作为首日挂牌的新股，其香港公开发售部分获得了高达4762.58倍的超额认购，显示出市场极高的认购热情和资金追捧。此前暗盘交易该股已录得显著涨幅，为上市首日的强势表现奠定了基调。天辰生物-B是一家临床阶段的生物制药公司，专注于针对过敏性及自身免疫性疾病的生物药物研发。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37d0231be6e823568bbf3b5d9ec33c9f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188921822","title":"异动解读｜天辰生物-B盘中上涨51.05%，首挂上市获超4762倍超额认购","url":"https://stock-news.laohu8.com/highlight/detail?id=1188921822","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188921822?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:30","pubTimestamp":1780623042,"startTime":"0","endTime":"0","summary":"6月5日，天辰生物-B首日挂牌上市，盘中上涨51.05%，报145.0港元，成交额3.02亿港元，较招股价96.06港元大幅溢价。消息面上，天辰生物-B本次IPO公开发售部分获4762.58倍超额认购，共接获约26.64万份有效申请，一手中签率仅约2%。此前暗盘交易报225.8港元，较招股价上涨逾135%，市场认购热情极高。天辰生物是一家临床阶段生物制药公司，专注于过敏性及自身免疫性疾病的生物药物自主发现与开发，核心产品LP-003为抗IgE抗体，已在中国启动八项临床试验。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37d0231be6e823568bbf3b5d9ec33c9f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641964196","title":"新股首日 | 天辰生物-B(01779)首挂上市 早盘高开50.22% 核心产品LP-003已在中国启动八项临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2641964196","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641964196?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:21","pubTimestamp":1780622509,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，天辰生物-B首挂上市，公告显示，每股定价96.06港元，共发行1419.32万股股份，每手50股，所得款项净额约12.55亿港元。截至发稿，涨50.22%，报144.3港元，成交额2.99亿港元。公开资料显示，天辰生物是一家临床阶段生物制药公司，主要专注于针对过敏性及自身免疫性疾病的生物药物的自主发现与开发。公司的核心产品LP-003是一种抗IgE抗体，已在中国启动八项临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37d0231be6e823568bbf3b5d9ec33c9f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107086499","title":"港股开盘 | 恒指低开0.27%，科指低开0.31%！天辰生物-B首挂涨超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107086499","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107086499?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:20","pubTimestamp":1780622430,"startTime":"0","endTime":"0","summary":"6月5日，恒生指数开盘下跌67.28点，跌幅0.27%，报25186.12点；恒生科技指数开盘下跌15.43点，跌幅0.31%，报4959.93点；国企指数开盘下跌8.36点，跌幅0.1%，报8493.55点；红筹指数开盘下跌25.99点，跌幅0.59%，报4394.52点。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37d0231be6e823568bbf3b5d9ec33c9f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02837","01779","09067","03417","09115","82800","07500","VXUS","03033","03067","02833","07200","07300","513600","83115","02800","BK4585","BK4588","03088","03423","03037","03115","09088","07226","03419","HSTECH","07552","HSI","03032"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127260818","title":"新股定价 | 天辰生物-B每股定价96.06港元，公开发售超购4762.58倍，一手中签率2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127260818","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127260818?lang=zh_cn&edition=full","pubTime":"2026-06-05 07:57","pubTimestamp":1780617420,"startTime":"0","endTime":"0","summary":"天辰生物-B（01779）公布配发结果。公司全球发售股份共计1419.315万股，最终发售价为每股96.06港元，募资净额约12.55亿港元，每手买卖单位为50股。H股预计于2026年6月5日（星期五）上午九时正起在联交所开始买卖。其中，香港公开发售部分获得4762.58倍超额认购，最终发售股份数目为141.94万股，占发售股份总数的10%。该部分共接获约26.64万份有效申请，受理申请数目约28057份，申购一手股份的获配发比例约为所申请股份总数的2%。国际配售部分获得10.94倍超额认购，最终发售股份数目为1277.38万股，占发售股份总数的90%。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/dd692af5834cccf0a1114930c5817827","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/dd692af5834cccf0a1114930c5817827"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37d0231be6e823568bbf3b5d9ec33c9f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640082163","title":"天辰生物-B(01779)：香港公开发售获4762.58倍认购 全球发售净筹约12.55亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640082163","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640082163?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:29","pubTimestamp":1780583353,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B(01779)公布配发结果，公司全球发售1419.315万股股份，香港公开发售占10%，国际发售占90%。最终发售价为每股96.06港元，全球发售净筹约12.55亿港元。每手50股，预期H股将于2026年6月5日(星期五)上午九时正(香港时间)开始在联交所买卖。其中，香港公开发售获4,762.58倍认购，国际发售获10.94倍认购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37d0231be6e823568bbf3b5d9ec33c9f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179817568","title":"天辰生物-B获4,763倍超购、募资逾13亿元　6月5日登陆港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=1179817568","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179817568?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:26","pubTimestamp":1780583185,"startTime":"0","endTime":"0","summary":"天辰生物医药（苏州）股份有限公司完成香港联交所主板上市前全球发售，招股价定为每股96.06港元。本次全球发售共发行14,193,150股H股，募资总额约13.63亿元港元，扣除预计开支后净筹约12.55亿元港元。公司股票预计于2026年6月5日挂牌买卖，股份代号01779，每手50股。公开发售部分获266,377份有效申请，认购倍数高达4,762.58倍；获接纳申请28,057份，最终分配1,419,350股H股，占全球发售10%。国际发售配售12,773,800股H股，获80名承配人认购，超额认购10.94倍，占本次发行90%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37d0231be6e823568bbf3b5d9ec33c9f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640584031","title":"新股暗盘 | 天辰生物-B(01779)暗盘盘初涨逾135% 每手赚6487港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640584031","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640584031?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:17","pubTimestamp":1780561037,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，天辰生物-B(01779)将于6月5日(周五)在香港挂牌。截至发稿，暗盘交易显示报价225.800港元，较招股价96.06港元上涨135.06%，每手50股，不计手续费，每手赚6487港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37d0231be6e823568bbf3b5d9ec33c9f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450092.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640192918","title":"新股消息 | 天辰生物-B(01779)招股结束 孖展认购达4624亿港元 超购3390倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2640192918","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640192918?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:25","pubTimestamp":1780385158,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，天辰生物-B5月28日起至6月2日招股。天辰生物计划发行1419.3万股H股，一成于香港作公开发售，发售价为每股96.06元，集资13.6亿元，每手50股，一手入场费4851.4元。天辰生物预期将于6月5日挂牌买卖，国金证券为独家保荐人。截至6月2日中午截飞，其公开部分录4624.4亿元孖展认购，以公开集资1.36亿元计，超购3390.8倍。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640955383","title":"新股孖展统计 | 6月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=2640955383","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640955383?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:39","pubTimestamp":1780310351,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大金重工(01081)、天辰生物-B(01779)、龙丰集团(02290)正在招股中。截至6月1日，富途证券、辉立证券等券商为大金重工借出174.59亿港元，超购逾29.23倍；为天辰生物借出1649.53亿港元，超购逾1208.84倍；为龙丰集团借出63.06亿港元，超购逾78.07倍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779","01081","02290"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640987634","title":"新股消息 | 天辰生物-B(01779)孖展认购额录得594亿港元 超购436倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2640987634","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640987634?lang=zh_cn&edition=full","pubTime":"2026-06-01 10:43","pubTimestamp":1780281813,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物制药公司天辰生物-B于2026年5月28日至2026年6月2日招股。根据市场消息，截至6月1日，天辰生物已获券商借出594亿港元孖展，以公开集资1.36亿港元计，超购436倍。天辰生物拟全球发售1419.32万股H股，其中，香港发售占10%，国际发售占90%，另有15%超额配股权。财务方面，由于天辰生物是尚未产生营收的生物科技公司，于往绩记录期间，公司并无产生任何收入或任何营业成本。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"新股消息 | 天辰生物-B(01779)孖展认购额录得594亿港元 超购436倍","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2639631624","title":"新股孖展统计 | 5月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=2639631624","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639631624?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:14","pubTimestamp":1780053288,"startTime":"0","endTime":"0","summary":"首钢朗泽(02553)招股结束，龙丰集团(02290)、天辰生物-B(01779)、大金重工(01081)正在招股中。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260529/20260529191514_44946.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260529/20260529191514_44946.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447912.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01081","02290","01779","02553","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638655242","title":"天辰生物-B于5月28日至6月2日招股 拟全球发售1419.32万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638655242","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638655242?lang=zh_cn&edition=full","pubTime":"2026-05-28 10:14","pubTimestamp":1779934492,"startTime":"0","endTime":"0","summary":"天辰生物-B于2026年5月28日至2026年6月2日招股，该公司拟全球发售1419.32万股H股，其中，香港发售占10%，国际发售占90%，另有15%超额配股权。假设超额配股权未获行使，公司目前拟将该等所得款项净额于未来3至5年内用于以下用途：约75.0%将主要用于核心产品及主要产品的研发及商业化；约15.0%将用于进一步开发其他临床前管线产品及研发平台；约10.0%将用作营运资金及其他一般企业用途。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/28101457233010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01779","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longbio.com","stockEarnings":[{"period":"1week","weight":0.0182},{"period":"1month","weight":0.4574},{"period":"ytd","weight":0.4574}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":-0.0531},{"period":"3month","weight":-0.0466},{"period":"6month","weight":-0.0537},{"period":"1year","weight":0.0138},{"period":"ytd","weight":-0.0514}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"天辰生物医药（苏州）股份有限公司是一家主要从事过敏性及自身免疫性疾病的生物药物自主发现与开发的中国公司。该公司的主要产品包括LP-003和LP-005。LP-003旨在治疗过敏性疾病，包括季节性AR、CSU、过敏性哮喘、食物过敏以及其他过敏性疾病。LP-005主要用于阵发性睡眠性血红蛋白尿症（PNH）、补体介导肾脏疾病、C3肾小球病（C3G）和狼疮性肾炎（LN）及其他补体相关适应症。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"天辰生物-B","nameEN":"LONGBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天辰生物-B(01779)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天辰生物-B(01779)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天辰生物-B,01779,天辰生物-B股票,天辰生物-B股票老虎,天辰生物-B股票老虎国际,天辰生物-B行情,天辰生物-B股票行情,天辰生物-B股价,天辰生物-B股市,天辰生物-B股票价格,天辰生物-B股票交易,天辰生物-B股票购买,天辰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天辰生物-B(01779)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天辰生物-B(01779)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}